Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Inventory (2018 - 2025)

10x Genomics' Inventory history spans 8 years, with the latest figure at $56.3 million for Q4 2025.

  • For Q4 2025, Inventory fell 32.21% year-over-year to $56.3 million; the TTM value through Dec 2025 reached $56.3 million, down 32.21%, while the annual FY2025 figure was $56.3 million, 32.21% down from the prior year.
  • Inventory for Q4 2025 was $56.3 million at 10x Genomics, down from $62.0 million in the prior quarter.
  • Across five years, Inventory topped out at $94.0 million in Q3 2024 and bottomed at $38.5 million in Q1 2021.
  • The 5-year median for Inventory is $74.2 million (2023), against an average of $71.0 million.
  • The largest annual shift saw Inventory soared 103.6% in 2021 before it crashed 34.12% in 2025.
  • A 5-year view of Inventory shows it stood at $60.0 million in 2021, then skyrocketed by 36.13% to $81.6 million in 2022, then decreased by 9.71% to $73.7 million in 2023, then increased by 12.75% to $83.1 million in 2024, then plummeted by 32.21% to $56.3 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Inventory are $56.3 million (Q4 2025), $62.0 million (Q3 2025), and $69.0 million (Q2 2025).